Spots Global Cancer Trial Database for brivanib
Every month we try and update this database with for brivanib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC | NCT03516071 | Hepatocellular ... | Brivanib 800 mg... Brivanib 400 mg... | 18 Years - 75 Years | Zai Lab (Hong Kong), Ltd. | |
| Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF | NCT01367275 | Colorectal Canc... Colorectal Aden... | Brivanib Irinotecan | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664) | NCT00435669 | Tumors | Brivanib Brivanib | 18 Years - | Bristol-Myers Squibb | |
| MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors | NCT00207103 | Tumors Neoplasm Metast... | Brivanib Brivanib Brivanib Brivanib Brivanib Brivanab | 18 Years - | Bristol-Myers Squibb | |
| First Line Hepato Cellular Carcinoma (HCC) | NCT00858871 | Hepato Cellular... | Brivanib Placebo Sorafenib Placebo | 18 Years - | Bristol-Myers Squibb | |
| A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer | NCT03895788 | Ovarian Cancer | niraparib Brivanib | 18 Years - | Hunan Cancer Hospital | |
| A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664) | NCT00437437 | Tumors | Brivanib | 18 Years - | Bristol-Myers Squibb | |
| Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment | NCT01108705 | Carcinoma, Hepa... | Brivanib Placebo | 18 Years - | Bristol-Myers Squibb | |
| Phase I/II Combination With Irinotecan- Erbitux | NCT00594984 | Metastatic Colo... | Cetuximab Irinotecan Brivanib Brivanib Brivanib Placeb... | 18 Years - | Bristol-Myers Squibb | |
| Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF | NCT01367275 | Colorectal Canc... Colorectal Aden... | Brivanib Irinotecan | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors | NCT00390936 | Solid Tumors | Brivanib | 20 Years - | Bristol-Myers Squibb | |
| A Study of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors | NCT00390936 | Solid Tumors | Brivanib | 20 Years - | Bristol-Myers Squibb | |
| Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment | NCT01108705 | Carcinoma, Hepa... | Brivanib Placebo | 18 Years - | Bristol-Myers Squibb | |
| Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC | NCT00908752 | Hepatocellular ... | Brivanib Brivanib Placeb... TACE Therapy | 18 Years - | Bristol-Myers Squibb | |
| Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC) | NCT01540461 | Hepatocellular ... | Brivanib | 18 Years - | Bristol-Myers Squibb | |
| A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC | NCT03516071 | Hepatocellular ... | Brivanib 800 mg... Brivanib 400 mg... | 18 Years - 75 Years | Zai Lab (Hong Kong), Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
